Valuation : Axonics, Inc.

Market Cap 362.77Cr 311.98Cr 293.43Cr 267.86Cr 500.96Cr 34TCr 502.59Cr 3.48TCr 1.34TCr 18TCr 1.36TCr 1.33TCr 56TCr P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 331.04Cr 284.69Cr 267.76Cr 244.43Cr 457.14Cr 31TCr 458.62Cr 3.17TCr 1.23TCr 16TCr 1.24TCr 1.22TCr 51TCr EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Director/Board Member 74 08/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Issuer sale

Executive/Senior Manager

59,355 0.1161%
15/11/24 Issuer sale

Responsable ventes & marketing

1,09,664 0.2145%
15/11/24 Issuer sale

Chief Technology Officer

63,237 0.1237%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+21.98% 362.77Cr
-1.58%-8.33%-22.73%+4.85% 12TCr
0.00%+0.14%-24.86%+1.96% 1.21TCr
-1.60%-1.33%+88.92%+131.23% 1.05TCr
-0.58%-1.20%-51.29%-71.01% 419.79Cr
-0.97%-9.65%-24.95%+35.52% 248.28Cr
-0.54%-5.73% - - 194.04Cr
+1.51%+2.67%-27.04%-73.72% 182.37Cr
-0.31%-4.00%-18.72%-24.58% 156.74Cr
Average -0.44%-1.73%-10.08%+3.28% 1.72TCr
Weighted average by Cap. -1.35%-6.44%-15.53%+10.87%

Financials

2022 2023
Net sales 27Cr 24Cr 22Cr 20Cr 38Cr 2.59TCr 38Cr 262.49Cr 101.46Cr 1.33TCr 102.79Cr 100.54Cr 4.22TCr 37Cr 32Cr 30Cr 27Cr 51Cr 3.46TCr 51Cr 351.38Cr 135.82Cr 1.77TCr 137.59Cr 134.58Cr 5.65TCr
Net income -5.97Cr -5.13Cr -4.83Cr -4.41Cr -8.24Cr -564.59Cr -8.27Cr -57Cr -22Cr -289.13Cr -22Cr -22Cr -920.95Cr -60.88L -52.36L -49.24L -44.95L -84.07L -58Cr -84.34L -5.84Cr -2.26Cr -29Cr -2.29Cr -2.24Cr -94Cr
Net Debt -35Cr -30Cr -28Cr -26Cr -48Cr -3.29TCr -48Cr -333.84Cr -129.04Cr -1.69TCr -130.72Cr -127.87Cr -5.37TCr -32Cr -27Cr -26Cr -23Cr -44Cr -3TCr -44Cr -304.35Cr -117.64Cr -1.54TCr -119.17Cr -116.57Cr -4.9TCr
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!